Prostate Cancer Program The Prostate Cancer Program (PCP) aims to advance and exploit scientific knowledge that will reduce the morbidity and mortality attributed to prostate cancer and lead to improvements in patients' quality of life. The PCP has three primary areas of focus where cooperative efforts (allocation of resources; faculty recruitments; scientific collaborations) are coordinated to make substantive advancements: 1) understanding the heritable and environmental risk factors contributing to prostate cancer development, progression, and lethality; 2) targeting mechanisms contributing to castration-resistant prostate cancer progression; and, 3) distinguishing lethal from indolent prostate cancer through discovery and validation of prognostic biomarkers and a treatment plan that affords longitudinal assessments and attenuation of risk. The P30 CCSG supports this research program by providing: key shared resources, particularly Comparative Medicine, Specimen Processing, Genomics, and Research Pathology; administrative and logistical support for PCP meetings, pilot funding for new clinical and translational research projects, and recruitment grants for new faculty. The Prostate Cancer Program currently has 32 members from 3 schools/divisions, 10 departments and 2 institutions. Eight members have primary appointments at FHCRC and 24 at UW. 29 Members (90%) have peer-reviewed funding, are PI on a clinical trial, or are newly recruited and supported by institutional funds. The current research support of PCP members comprises $6.5M in peer-reviewed funding of which $4.4M (68%) is from the NCI (direct dollars.) Due to the efforts in promoting inter-disciplinary studies, a substantial component of the research funding is in the form of P50, P01, and other collaborative grants. Of the 417 newly treated prostate cancer patients, 66 (16%) were enrolled onto therapeutic clinical trials in 2013. The program published a total of 458 papers in the previous grant period. 24% were inter-institutional, 32% were intra-programmatic and 20% were inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617728
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mora-Pinzon, Maria C; Trentham-Dietz, Amy; Gangnon, Ronald E et al. (2018) Urinary Magnesium and Other Elements in Relation to Mammographic Breast Density, a Measure of Breast Cancer Risk. Nutr Cancer 70:441-446
Shirts, Brian H; Konnick, Eric Q; Upham, Sarah et al. (2018) Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. Am J Hum Genet 103:19-29
Du, Jing; Flynn, Ryan; Paz, Katelyn et al. (2018) Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131:1743-1754
Suzuki, Aussie; Gupta, Amitabha; Long, Sarah K et al. (2018) A Kinesin-5, Cin8, Recruits Protein Phosphatase 1 to Kinetochores and Regulates Chromosome Segregation. Curr Biol 28:2697-2704.e3
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis. J Cell Sci 131:
Kuzma, Jessica N; Hagman, Derek K; Cromer, Gail et al. (2018) Intra-individual variation in markers of intestinal permeability and adipose tissue inflammation in healthy normal weight to obese adults. Cancer Epidemiol Biomarkers Prev :
Adrianse, Robin L; Smith, Kaleb; Gatbonton-Schwager, Tonibelle et al. (2018) Perturbed maintenance of transcriptional repression on the inactive X-chromosome in the mouse brain after Xist deletion. Epigenetics Chromatin 11:50
Walter, Roland B; Othus, Megan; Orlowski, Kaysey F et al. (2018) Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica 103:e106-e109
Thornblade, Lucas W; Mulligan, Michael S; Odem-Davis, Katherine et al. (2018) Challenges in Predicting Recurrence After Resection of Node-Negative Non-Small Cell Lung Cancer. Ann Thorac Surg 106:1460-1467
Nambiar, Mridula; Smith, Gerald R (2018) Pericentromere-Specific Cohesin Complex Prevents Meiotic Pericentric DNA Double-Strand Breaks and Lethal Crossovers. Mol Cell 71:540-553.e4

Showing the most recent 10 out of 1267 publications